U.S. Biosimilar Guidances: Bridging, Extrapolation And Immunogenicity
This article was originally published in PharmAsia News
Executive Summary
New draft Q&A and three final guidances from the U.S. FDA offer pros and cons for sponsors of biosimilar applications in this major market and provide substantial additional details on the agency’s regulatory approach to such products.